The full text of this article can be found here: https://link.springer.com/article/10.1007/s40265-017-0797-
Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms a...
The online version of this article, along with updated information and services, is located o
<p>Primary myelofibrosis (PMF) is one of the diseases that cannot be cured using modern methods of c...
Contains fulltext : 89048.pdf (publisher's version ) (Closed access)Primary myelof...
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase
Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly, constitutional symptom...
Myelofibrosis (MF) is a BCR/ABL-negative myeloproliferative neoplasm characterized by clonal myelopr...
Julian A Waksal, Douglas Tremblay, John Mascarenhas Department of Hematology and Oncology, Tisch Can...
The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue i...
Clodagh Keohane, Deepti H Radia, Claire N HarrisonDepartment of Haematology, Guy's and St Thomas...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
Primary myelofibrosis (PMF) is a chronic myeloprolif-erative disorder associated with an average sur...
agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study a...
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal...
Dahniel Sastow,1 Douglas Tremblay2 1Department of Internal Medicine, Icahn School of Medicine at Mou...
Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms a...
The online version of this article, along with updated information and services, is located o
<p>Primary myelofibrosis (PMF) is one of the diseases that cannot be cured using modern methods of c...
Contains fulltext : 89048.pdf (publisher's version ) (Closed access)Primary myelof...
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase
Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly, constitutional symptom...
Myelofibrosis (MF) is a BCR/ABL-negative myeloproliferative neoplasm characterized by clonal myelopr...
Julian A Waksal, Douglas Tremblay, John Mascarenhas Department of Hematology and Oncology, Tisch Can...
The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue i...
Clodagh Keohane, Deepti H Radia, Claire N HarrisonDepartment of Haematology, Guy's and St Thomas...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
Primary myelofibrosis (PMF) is a chronic myeloprolif-erative disorder associated with an average sur...
agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study a...
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal...
Dahniel Sastow,1 Douglas Tremblay2 1Department of Internal Medicine, Icahn School of Medicine at Mou...
Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms a...
The online version of this article, along with updated information and services, is located o
<p>Primary myelofibrosis (PMF) is one of the diseases that cannot be cured using modern methods of c...
DOI
Add to ORKG